General Pharmacology — MCQs

General Pharmacology Indian Medical PG Practice Questions and MCQs

Question 261: All of the following drugs cause hemolysis in patients with G-6-PD deficiency except?

A. Primaquine
B. Chloroquine
C. Quinine
D. Atropine (Correct Answer)

Explanation: Glucose-6-Phosphate Dehydrogenase (G-6-PD) deficiency is an X-linked recessive disorder [1] where erythrocytes lack the ability to regenerate reduced **glutathione**. This makes them highly susceptible to oxidative stress, leading to hemoglobin denaturation (Heinz bodies) and hemolysis when exposed to certain oxidizing agents. **Why Atropine is the correct answer:** **Atropine** is a muscarinic antagonist (anticholinergic). It does not possess oxidizing properties and does not interfere with the redox machinery of the red blood cell. Therefore, it is safe to use in G-6-PD deficient patients. **Analysis of incorrect options:** * **Primaquine:** This is the classic "high-risk" drug for G-6-PD deficiency. It is an 8-aminoquinoline that generates reactive oxygen species (ROS), causing severe oxidative hemolysis [1]. * **Chloroquine & Quinine:** Both are antimalarials that can induce hemolysis in G-6-PD deficient individuals, though the risk is significantly lower compared to Primaquine. They are generally considered "intermediate risk" but are contraindicated or require close monitoring in severe deficiency. **High-Yield Clinical Pearls for NEET-PG:** * **Common Triggers:** Mnemonic **"AAA"** – **A**ntimalarials (Primaquine), **A**ntibiotics (Sulfonamides, Nitrofurantoin, Dapsone), and **A**spirin (in high doses). Fava beans (Favism) are a classic dietary trigger. * **Diagnosis:** Peripheral smear shows **Heinz bodies** (denatured hemoglobin) and **Bite cells** (result of splenic macrophages removing Heinz bodies). * **Key Contraindication:** Never give Primaquine without screening for G-6-PD levels, as it can precipitate a life-threatening hemolytic crisis.

Question 262: Sodium and/or potassium ions are involved in the mechanism of action of which of the following receptors?

A. Dopamine receptor
B. Neuromuscular (Nm) receptor
C. Neuronal (Nn) receptor
D. All of the above (Correct Answer)

Explanation: **Explanation:** The correct answer is **All of the above** because all three receptors listed are linked to ion channels (either directly or indirectly) that regulate the flux of sodium ($Na^+$) and/or potassium ($K^+$) ions. 1. **Neuromuscular ($N_m$) and Neuronal ($N_n$) Receptors:** These are **Ionotropic receptors** (Ligand-gated ion channels). When Acetylcholine binds to these nicotinic receptors, it causes the opening of a central pore that is permeable to both $Na^+$ and $K^+$. The rapid influx of $Na^+$ leads to depolarization, which triggers an action potential (muscle contraction in $N_m$ and post-ganglionic firing in $N_n$). 2. **Dopamine Receptors:** These are **Metabotropic receptors** (G-Protein Coupled Receptors - GPCRs). While they don't form a channel themselves, their downstream signaling significantly affects ion conductance. For example, $D_2$ receptors are coupled to $G_i/G_o$ proteins, which often lead to the **opening of $K^+$ channels** (causing hyperpolarization) and the **inhibition of $Na^+$ or $Ca^{2+}$ channels**. **Why "All of the above" is correct:** While the mechanism differs (direct gating for Nicotinic vs. indirect modulation for Dopamine), all three receptors fundamentally rely on the movement of $Na^+$ and/or $K^+$ to exert their physiological effects. **High-Yield Clinical Pearls for NEET-PG:** * **Nicotinic Receptors ($N_m, N_n$):** Always excitatory; work via rapid $Na^+$ influx. * **G-Protein Modulation:** $G_i$ coupled receptors (like $D_2, M_2, \alpha_2$) typically increase $K^+$ efflux, leading to membrane stabilization/hyperpolarization. * **Fast vs. Slow:** Ionotropic receptors (Nicotinic) act in milliseconds, whereas Metabotropic (Dopamine) act in seconds to minutes.

Question 263: The fall in blood pressure caused by d-tubocurarine is due to which of the following mechanisms?

A. Reduced venous return
B. Ganglionic blockade
C. Histamine release
D. All of the above (Correct Answer)

Explanation: **Explanation:** **d-Tubocurarine (d-TC)** is a prototype non-depolarizing neuromuscular blocker that causes a significant fall in blood pressure through a multi-factorial mechanism: 1. **Histamine Release:** d-TC is a potent inducer of mast cell degranulation. The released histamine causes systemic vasodilation and increased capillary permeability, leading to a drop in peripheral vascular resistance and blood pressure. 2. **Ganglionic Blockade:** At therapeutic doses, d-TC can block nicotinic receptors ($N_n$) at the autonomic ganglia. This reduces sympathetic outflow to the blood vessels, further contributing to hypotension. 3. **Reduced Venous Return:** The drug causes profound skeletal muscle relaxation. The loss of the "skeletal muscle pump" action, combined with the vasodilation mentioned above, leads to peripheral pooling of blood and a subsequent decrease in venous return to the heart. **Why "All of the above" is correct:** Since d-TC simultaneously triggers histamine release, inhibits autonomic ganglia, and reduces the muscle pump effect, all three mechanisms synergistically contribute to the observed hypotension. **Clinical Pearls for NEET-PG:** * **Mnemonic:** d-Tubocurarine "**T**errible" for BP (Histamine + Ganglia). * **Modern Alternatives:** Newer agents like **Vecuronium** and **Rocuronium** are preferred in clinical practice because they lack histamine-releasing and ganglion-blocking properties, making them cardiovascularly stable. * **Atracurium:** Also causes histamine release but is unique for its metabolism via **Hofmann elimination** (spontaneous degradation), making it safe in liver and kidney failure. * **Antidote:** Hypotension caused by d-TC is managed with fluids and vasopressors, while the neuromuscular block is reversed using **Neostigmine** (plus Glycopyrrolate).

Question 264: What is the characteristic shape of a dose-response curve demonstrating hormesis?

A. Straight line
B. Sigmoid
C. Inverted U or J shaped (Correct Answer)
D. Hyperbola

Explanation: **Explanation:** **Hormesis** is a dose-response phenomenon characterized by a low-dose stimulation and a high-dose inhibition. It represents an adaptive response of biological systems to moderate environmental or chemical stress. 1. **Why "Inverted U or J shaped" is correct:** * **Inverted U-shape:** When plotting the **beneficial/stimulatory effect** on the Y-axis, the curve rises at low doses (stimulation) and falls at high doses (toxicity/inhibition). * **J-shape:** When plotting **adverse effects/mortality** on the Y-axis, the curve initially drops below the control level at low doses (protective effect) and then rises sharply at higher doses (toxic effect). * *Example:* Moderate alcohol consumption may decrease cardiovascular mortality (low dose), while excessive consumption increases it (high dose). 2. **Why other options are incorrect:** * **Straight line:** Represents a linear relationship where the effect is directly proportional to the dose (e.g., certain genotoxic carcinogens in some models). * **Sigmoid (S-shaped):** This is the **standard log dose-response curve** for most drugs, showing a threshold, a linear phase, and a maximal effect (Emax). * **Hyperbola:** This is the shape of a **standard dose-response curve** when the dose is plotted on an arithmetic scale (not log scale). **High-Yield Clinical Pearls for NEET-PG:** * **Concept:** "What is toxic at high concentrations can be beneficial at low concentrations." * **Clinical Examples:** * **Digitalis:** Increases cardiac contractility at therapeutic doses but causes arrhythmias at toxic doses. * **Exercise:** Moderate stress improves health; extreme overexertion causes injury. * **Radiation:** Low-dose radiation may stimulate DNA repair mechanisms. * **Key Distinction:** Unlike the standard "Threshold Model," hormesis suggests that the "No Observed Adverse Effect Level" (NOAEL) is preceded by a stimulatory phase.

Question 265: Tolerance and physical dependence may occur after chronic use of all of the following agents EXCEPT?

A. Meperidine
B. Phenobarbital
C. Diazepam
D. Clomipramine (Correct Answer)

Explanation: **Explanation:** The core concept tested here is the distinction between drugs with **abuse potential** (which lead to tolerance and physical dependence) and those used for psychiatric conditions that do not typically cause addiction. **1. Why Clomipramine is the correct answer:** Clomipramine is a **Tricyclic Antidepressant (TCA)**. While TCAs can cause "discontinuation syndrome" (cholinergic rebound) if stopped abruptly, they **do not** produce true physical dependence or tolerance in the pharmacological sense. They do not activate the brain's reward system (mesolimbic dopaminergic pathway), and therefore, patients do not develop a craving or a need for escalating doses to achieve the same effect. **2. Why the other options are incorrect:** * **Meperidine (Pethidine):** An opioid agonist. All opioids are notorious for causing rapid tolerance (to analgesia and euphoria) and severe physical dependence characterized by a specific withdrawal syndrome. * **Phenobarbital:** A long-acting barbiturate. Barbiturates induce hepatic enzymes (leading to pharmacokinetic tolerance) and alter GABA receptor sensitivity (pharmacodynamic tolerance). Abrupt withdrawal can be life-threatening, involving seizures. * **Diazepam:** A benzodiazepine. Chronic use leads to down-regulation of GABA-A receptors. This results in both tolerance to its sedative/anxiolytic effects and physical dependence. **High-Yield Clinical Pearls for NEET-PG:** * **Tolerance** is a state where a higher dose is required to produce the same effect. * **Physical Dependence** is an altered physiological state produced by repeated administration of a drug, necessitating its continued presence to maintain physiological equilibrium. * **Drugs NOT causing dependence:** Antipsychotics, Antidepressants (TCAs, SSRIs), and NSAIDs. * **Meperidine unique fact:** Unlike other opioids, it can cause **mydriasis** (due to its atropine-like action) and seizures (due to its metabolite, normeperidine).

Question 266: Prostaglandins are used in all except?

A. Cervical ripening
B. Postpartum hemorrhage (PPH)
C. Erectile dysfunction
D. Palliative treatment of Patent Ductus Arteriosus (PDA) (Correct Answer)

Explanation: The correct answer is **D. Palliative treatment of Patent Ductus Arteriosus (PDA)**. ### **Explanation of the Correct Answer** The goal in managing a **Patent Ductus Arteriosus (PDA)** is usually to **close** it, not maintain it. Prostaglandins (specifically PGE1) are used to **keep the ductus arteriosus open** in neonates with ductal-dependent congenital heart defects (e.g., Transposition of the Great Arteries) [1, 2]. To treat/close a PDA, **NSAIDs** (Prostaglandin synthesis inhibitors) like **Indomethacin** or **Ibuprofen** are used. Therefore, prostaglandins are not used for the treatment of PDA itself. ### **Analysis of Incorrect Options** * **A. Cervical Ripening:** **PGE2 (Dinoprostone)** and **PGE1 (Misoprostol)** are gold-standard agents used to soften the cervix and induce labor by increasing proteoglycan synthesis and collagenase activity [1, 2, 3, 4]. * **B. Postpartum Hemorrhage (PPH):** **PGF2α (Carboprost)** and **PGE1 (Misoprostol)** are potent uterotonics used to control bleeding by causing strong uterine contractions when oxytocin is insufficient [2, 4]. * **C. Erectile Dysfunction:** **PGE1 (Alprostadil)** can be injected intracavernosally or applied intraurethrally. It acts as a vasodilator by increasing cAMP, facilitating an erection [2]. ### **High-Yield NEET-PG Pearls** * **Alprostadil (PGE1):** Used for maintaining ductal patency (pre-surgery) and Erectile Dysfunction [1, 2]. * **Misoprostol (PGE1):** Used for NSAID-induced peptic ulcers, medical abortion (with Mifepristone), and PPH [2, 3, 4]. * **Latanoprost (PGF2α):** First-line for Open-Angle Glaucoma (increases uveoscleral outflow) [2, 3]. * **Epoprostenol (PGI2):** Used in Pulmonary Arterial Hypertension [2]. * **Closure of PDA:** Remember the mnemonic "Come In" (**C**lose with **I**ndomethacin); **Keep Open** with **PGE1** [1, 2].

Question 267: Which of the following are prodrugs?

A. Mercaptopurine
B. Dipivefrine
C. Enalapril
D. All of these (Correct Answer)

Explanation: **Explanation:** A **prodrug** is a pharmacologically inactive compound that must undergo chemical or enzymatic biotransformation within the body to be converted into its active metabolite. This strategy is often used to improve bioavailability, reduce toxicity, or enhance site-specificity. * **Mercaptopurine (Option A):** This is a purine analogue used in leukemia. It is inactive in its parent form and must be converted by the enzyme **HGPRT** into **6-thioinosinic acid** (the active nucleotide) to inhibit DNA synthesis. * **Dipivefrine (Option B):** It is a prodrug of **Epinephrine** used in glaucoma. Being more lipophilic than epinephrine, it penetrates the cornea much more effectively. Once inside the eye, it is hydrolyzed by esterases into active epinephrine. * **Enalapril (Option C):** Most ACE inhibitors (except Captopril and Lisinopril) are prodrugs. Enalapril is converted by hepatic esterases into **Enalaprilat**, which is the potent inhibitor of the Angiotensin-Converting Enzyme. Since all three medications require metabolic activation, **Option D** is the correct answer. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Prodrugs:** "**A**ll **P**rodrugs **C**an **E**nter **D**e **L**iver **M**aking **S**ome **P**otent **H**ormones" (**A**CEIs (except Capto/Lisino), **P**roton Pump Inhibitors, **C**yclophosphamide, **E**nalapril, **D**opa (L-Dopa), **L**evodopa, **M**ercaptopurine, **S**ulindac, **P**rednisone, **H**eroin). * **Exceptions:** **Captopril and Lisinopril** are the only ACE inhibitors that are **NOT** prodrugs. * **Advantage:** Prodrugs like **Levodopa** can cross the blood-brain barrier, whereas the active form (Dopamine) cannot.

Question 268: What is meant by drug efficacy?

A. The effectiveness of a drug in life-threatening conditions.
B. The maximal intensity of response that can be produced by a drug. (Correct Answer)
C. The dose of the drug needed to produce half of the maximal effect.
D. The minimum dose of the drug needed to produce a toxic effect.

Explanation: ### Explanation **1. Why Option B is Correct:** **Drug Efficacy** (also known as maximal efficacy or intrinsic activity) refers to the **maximal response ($E_{max}$)** that can be elicited by a drug, regardless of the dose. It is a measure of a drug's ability to activate a receptor once it has bound to it. On a Dose-Response Curve (DRC), efficacy is represented by the **height (peak)** of the curve. Clinical effectiveness is determined primarily by efficacy rather than potency. **2. Why the Other Options are Incorrect:** * **Option A:** This describes "clinical effectiveness" in a specific scenario but is not a pharmacological definition of efficacy. * **Option C:** This defines **Potency** ($EC_{50}$ or $ED_{50}$). Potency refers to the amount of drug required to produce a specific effect. On a DRC, potency is represented by the **position of the curve on the X-axis** (left-shifting indicates higher potency). * **Option D:** This refers to the **Minimum Toxic Dose**. The relationship between the therapeutic dose and the toxic dose is expressed as the **Therapeutic Index**. **3. NEET-PG High-Yield Pearls:** * **Efficacy vs. Potency:** A drug can be highly potent but have low efficacy (e.g., a drug that works at microgram doses but only reduces blood pressure by 5 mmHg). In clinical practice, **efficacy is more important than potency.** * **Full Agonists** have an intrinsic activity of 1 (maximal efficacy). * **Antagonists** have an intrinsic activity of 0 (they bind but produce no response). * **Partial Agonists** have an intrinsic activity between 0 and 1; they can act as antagonists in the presence of a full agonist. * **Inverse Agonists** have an intrinsic activity between 0 and -1 (they produce an effect opposite to the agonist).

Question 269: The enzyme pseudocholinesterase acts on which of the following drugs?

A. Decamethonium
B. Tubocurarine
C. Gallamine
D. Suxamethonium (Correct Answer)

Explanation: **Explanation:** **Correct Answer: D. Suxamethonium** **Mechanism:** Suxamethonium (Succinylcholine) is a depolarizing neuromuscular blocker. Its short duration of action (5–10 minutes) is due to its rapid hydrolysis by **Pseudocholinesterase** (also known as Butyrylcholinesterase or Plasma Cholinesterase), which is synthesized in the liver and found in the plasma. Unlike Acetylcholine, Suxamethonium is not metabolized by Acetylcholinesterase at the motor endplate. **Analysis of Incorrect Options:** * **A. Decamethonium:** Although it is a depolarizing blocker like Suxamethonium, it is not metabolized by cholinesterases; it is excreted unchanged in the urine. * **B. Tubocurarine:** This is a long-acting non-depolarizing blocker. It is primarily excreted in the urine (70%) and bile, and is not metabolized by pseudocholinesterase. * **C. Gallamine:** This is another non-depolarizing blocker that is excreted entirely unchanged by the kidneys. **NEET-PG High-Yield Pearls:** 1. **Suxamethonium Apnea:** Patients with a genetic deficiency or atypical variant of pseudocholinesterase (detected by a low **Dibucaine Number**) cannot metabolize the drug, leading to prolonged paralysis and respiratory failure. 2. **Site of Synthesis:** Pseudocholinesterase is produced in the **liver**. Its levels may decrease in chronic liver disease, leading to prolonged Suxamethonium action. 3. **Drugs metabolized by Pseudocholinesterase:** Remember the mnemonic **"P-M-C-S"**: **P**rocaine, **M**ivacurium, **C**ocaine, and **S**uxamethonium. 4. **Antidote:** There is no specific pharmacological reversal for Suxamethonium; management of apnea is via mechanical ventilation and fresh frozen plasma (which contains the enzyme).

Question 270: Which of the following is NOT known as an immunosuppressive agent?

A. Prednisolone
B. Cephalosporin (Correct Answer)
C. Azathioprine
D. Cyclosporin

Explanation: **Explanation:** The correct answer is **B. Cephalosporin**. **Why Cephalosporin is the correct answer:** Cephalosporins are a class of **β-lactam antibiotics** derived from the fungus *Acremonium*. They function by inhibiting bacterial cell wall synthesis (binding to penicillin-binding proteins). They possess **antimicrobial** properties, not immunosuppressive ones. While they treat infections, they do not suppress the host's immune response. **Analysis of Incorrect Options:** * **A. Prednisolone:** A potent **Glucocorticoid** that suppresses the immune system by inhibiting NF-κB, decreasing the production of pro-inflammatory cytokines (IL-1, IL-6), and inducing apoptosis of T-lymphocytes. * **C. Azathioprine:** A **Purine Antimetabolite** (prodrug of 6-mercaptopurine). It inhibits DNA synthesis, thereby preventing the proliferation of rapidly dividing cells, particularly T and B lymphocytes. * **D. Cyclosporin:** A **Calcineurin Inhibitor**. It binds to cyclophilin to inhibit calcineurin, preventing the dephosphorylation of NFAT (Nuclear Factor of Activated T-cells). This specifically inhibits the transcription of **Interleukin-2 (IL-2)**, a key driver of T-cell proliferation. **High-Yield Clinical Pearls for NEET-PG:** * **Confusion Alert:** Do not confuse **Cyclosporin** (Immunosuppressant) with **Cephalosporin** (Antibiotic) due to their similar phonetic endings. * **Cyclosporin Side Effects:** Remember the "6 H's"—Hypertrichosis (hirsutism), Hyperplasia of gums, Hypertension, Hyperlipidemia, Hyperkalemia, and Hepatotoxicity/Nephrotoxicity. * **Drug of Choice:** Azathioprine is frequently used in steroid-sparing regimens for autoimmune diseases like SLE and Rheumatoid Arthritis.

Practice by Chapter

Pharmacokinetics: Absorption and Distribution

Practice Questions

Pharmacokinetics: Metabolism and Excretion

Practice Questions

Pharmacodynamics and Receptor Theory

Practice Questions

Drug-Receptor Interactions and Dose-Response

Practice Questions

Pharmacogenetics and Personalized Medicine

Practice Questions

Adverse Drug Reactions and Toxicity

Practice Questions

Drug Interactions

Practice Questions

Drug Development and Regulation

Practice Questions

Pediatric and Geriatric Pharmacology

Practice Questions

Placental Transfer and Lactation

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free